{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:38:01Z","timestamp":1783021081853,"version":"3.54.6"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijid.2025.108189","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T02:02:23Z","timestamp":1762567343000},"page":"108189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Supporting equitable booster strategies: one-year real-world immunogenicity data in people with HIV (PWH) receiving different variant-adapted COVID-19 vaccines"],"prefix":"10.1016","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6944-0686","authenticated-orcid":false,"given":"Alessandra","family":"Vergori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Matusali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Cozzi","family":"Lepri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2659-0868","authenticated-orcid":false,"given":"Eleonora","family":"Cimini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Colavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozenn","family":"Esvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Gili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Cristofanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mazzotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.108189_bib0001","article-title":"Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study","volume":"35","author":"Evans","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"14","key":"10.1016\/j.ijid.2025.108189_bib0002","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent Omicron-containing booster vaccine against COVID-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.108189_bib0003","unstructured":"Vaccino COVID19 Nuvaxovid. Available at: https:\/\/www.aifa.gov.it\/vaccino-covid-19-nuvaxovid"},{"issue":"5","key":"10.1016\/j.ijid.2025.108189_bib0004","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1473-3099(24)00670-4","article-title":"Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2\/3 study","volume":"25","author":"Alves","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2025.108189_bib0005","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac238","volume":"75","author":"Antinori","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.ijid.2025.108189_bib0006","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.3390\/ijms26083521","article-title":"Immune response against recent omicron sub-lineages in persons with HIV receiving a protein-based or mRNA XBB.1.5 SARS-CoV-2 booster vaccine","volume":"26","author":"Vergori","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.ijid.2025.108189_bib0007","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ijid.2025.108189_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105385","article-title":"Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID","volume":"109","author":"Chen","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijid.2025.108189_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104661","article-title":"Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV - a prospective observational cohort study","volume":"93","author":"Heftdal","year":"2023","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.ijid.2025.108189_bib0010","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3390\/vaccines11121739","article-title":"Long term assessment of Anti-SARS-CoV-2 immunogenicity after mRNA vaccine in persons living with HIV","volume":"11","author":"Vergori","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.ijid.2025.108189_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0323792","article-title":"Longitudinal assessment of COVID-19 vaccine immunogenicity in people with HIV stratified by CD4+ T-cell count in the Netherlands: a two-year follow-up study","volume":"20","author":"Jongkees","year":"2025","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ijid.2025.108189_bib0012","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41541-024-00972-3","article-title":"Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections","volume":"9","author":"Alirezaylavasani","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.ijid.2025.108189_bib0013","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0000000000003429","article-title":"Anis AH; COVAXHIV Study Group. COVID-19 vaccine immunogenicity in people with HIV","volume":"37","author":"Costiniuk","year":"2023","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.ijid.2025.108189_bib0014","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s43856-025-00799-6","article-title":"Long-term immune responses to SARS-CoV-2 Omicron BA.4\/5 mRNA booster in people living with HIV","volume":"5","author":"Augello","year":"2025","journal-title":"Commun Med (Lond)"},{"issue":"728","key":"10.1016\/j.ijid.2025.108189_bib0015","doi-asserted-by":"crossref","first-page":"eadd5960","DOI":"10.1126\/scitranslmed.add5960","article-title":"Adjuvanted SARS-CoV-2 spike protein vaccination elicits long-lived plasma cells in nonhuman primates","volume":"16","author":"Prabhakaran","year":"2024","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.ijid.2025.108189_bib0016","first-page":"1025","article-title":"The Matrix-M\u2122 adjuvant: a key component in Novavax COVID-19 vaccine and beyond","volume":"22","author":"Stertman","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ijid.2025.108189_bib0017","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41541-023-00638-6","article-title":"SARS-CoV-2 spike ferritin nanoparticle vaccine adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies in nonhuman primates","volume":"8","author":"Shrivastava","year":"2023","journal-title":"Npj Vaccines"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225004114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225004114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:49:15Z","timestamp":1783018155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225004114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":17,"alternative-id":["S1201971225004114"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108189","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Supporting equitable booster strategies: one-year real-world immunogenicity data in people with HIV (PWH) receiving different variant-adapted COVID-19 vaccines","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108189"}}